Denali Therapeutics Inc (DNLI)

$16.82 0.52 (3.00%)

16:00 EDT DNLI Stock Quote Delayed 30 Minutes

To the Moon and Beyond: 7 Stocks With Cosmic Potential

By Muslim Farooque, InvestorPlace Contributor Mar 14, 2024

With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential

3 Biotech Stocks to Buy for the Next Bull Run: February 2024

3 Biotech Stocks at the Forefront of the Quest for Eternal Youth

Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now

More Articles

Volume:

Previous Close -

Market Cap 2.05B

PE Ratio -15.43

EPS -1.09

Volume (Avg. Vol.) 1.37M

Day's Range $16.79 - $17.56

52-Week Range $15.45 - $33.31

Dividend & Yield N/A (N/A)

DNLI Stock Predictions, Articles, and Denali Therapeutics Inc News

From InvestorPlace
From the Web

7 F-Rated Stocks to Avoid During the Downturn

By Louis Navellier and the InvestorPlace Research Staff Mar 23, 2022

It's easy to find hard hit stocks in this market, but what's harder to determine is which stocks are truly F-rated stocks among the losers.

7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines

By Louis Navellier and the InvestorPlace Research Staff Mar 12, 2021

If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks.

7 Biotech Stocks To Buy Beyond Covid Vaccine Plays

By Louis Navellier and the InvestorPlace Research Staff Dec 14, 2020

It’s a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.

7 Big Biotech Stocks to Avoid

By Louis Navellier, Editor, Growth Investor Jan 28, 2020

The only thing more important than what to buy is what not to buy. These biotech stocks are at the top of the avoid list. Here's why.

Denali spikes after $500M private placement (NASDAQ:DNLI)

From Seeking Alpha Feb 27, 2024

Denali Therapeutics (DNLI) stock rises amid plans to raise $500M through a private placement. Read more here.

Citi starts Denali at buy, sees catalyst-rich window starting in 2024 (NASDAQ:DNLI)

From Seeking Alpha Dec 13, 2023

Citi has initiated coverage of Denali (DNLI) with a buy rating, citing its deep pipeline, strong science, low valuation and upcoming catalysts. Read more here.

JP Morgan bullish on six Big Biotechs, rates nine others neutral or lower (NASDAQ:INSM)

From Seeking Alpha Nov 25, 2023

JP Morgan said it was bullish on Insmed (INSM), Denali (DNLI), Immunocore (IMCR), Crinetics (CRNX), Mirum (MIRM) and BioCryst (BCRX), rating all as overweight. Read more here.

Biogen, Denali halt trial for Parkinson’s disease drug (NASDAQ:DNLI)

From Seeking Alpha Jun 5, 2023

Denali Therapeutics (DNLI) announced Monday that the company and partner Biogen (BIIB) would halt a Phase 3 trial for Parkinson’s disease drug BIIB122. Read more here.

Why Shares of Denali Therapeutics Are Up Monday

From The Motley Fool May 15, 2023

Analysts maintained their buy ratings on the clinical-stage biotech company.

Analysts Offer Insights on Healthcare Companies: Mirati Therapeutics (MRTX) and Denali Therapeutics (DNLI)

From TipRanks Dec 6, 2022

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mirati Therapeutics (MRTX – Research Report) and Den...

ADVERTISEMENT